PI
RVNC

PFS Investments’s Revance Therapeutics, Inc. RVNC Stock Holding History

PFS Investments’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$273K Buy
10,799
+1,512
+16% +$47.1K ﹤0.01% 454
2023
Q1 		$316K Buy
+9,287
New +$290K 0.01% 425

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PFS Investments's RVNC Position: Q2 2023 in Review

PFS Investments increased its Revance Therapeutics, Inc. (RVNC) stake by 16% in Q2 2023, buying an estimated $47.1K and bringing the position to 10,799 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #454.

PFS Investments first reported a position in RVNC in Q1 2023 and has held it in 2 quarters since. The position peaked at $316K in Q1 2023. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

  • PFS Investments held 10,799 shares of Revance Therapeutics, Inc. worth $273K as of Q2 2023.
  • PFS Investments bought 1,512 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $47.1K.
  • Revance Therapeutics, Inc. made up ﹤0.01% of PFS Investments's portfolio in Q2 2023, its #454 holding.
  • PFS Investments first reported a position in Revance Therapeutics, Inc. in Q1 2023 and has held it in 2 quarters since.
  • PFS Investments's Revance Therapeutics, Inc. position peaked at $316K in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on PFS Investments's 13F filing for Q2 2023, filed 14 Aug 2023.